Latest News
Collegium Pharmaceutical, Inc.
- Collegium to Report Third Quarter 2026 Financial Results on November 5, 2026
- Collegium Pharmaceutical Announces Seven ADHD Abstracts Accepted for AACAP and NEI Fall Congresses
- Collegium to Present Pediatric and Real-World Research Across ADHD Portfolio at AACAP and NEI Fall Congresses
- Zacks upgrades Collegium Pharmaceutical stock to strong buy
- Grunenthal license termination adds near-term upside for Collegium
- Collegium Paid $17 Million to Settle Nucynta ER Patent Dispute
- Zacks upgrades Collegium Pharmaceutical stock to strong buy
- Collegium Pharmaceutical: Under 3x Cash Earnings After A Narrow Guidance Cut (NASDAQ:COLL)
- Collegium Pharmaceutical - Co And Grünenthal Enter Settlement Agreement On Oct 15, 2026 - SEC Filing
- Collegium Pharmaceutical Outlook Supported by ADHD Trends, Low Generic Drug Risk, Oppenheimer Says
- Four investors report shared voting power over Collegium Pharma (COLL) shares.
- Collegium Launches "Start Talking ADHD" with Practical
Headlines from the last 30 days, linking to the original publishers. See all market news →